IBDEI0J1 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8317,0)
 ;;=M32.0^^65^530^19
 ;;^UTILITY(U,$J,358.3,8317,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8317,1,3,0)
 ;;=3^Lupus,Erythematosus,Drug-Induced Systemic
 ;;^UTILITY(U,$J,358.3,8317,1,4,0)
 ;;=4^M32.0
 ;;^UTILITY(U,$J,358.3,8317,2)
 ;;=^5011752
 ;;^UTILITY(U,$J,358.3,8318,0)
 ;;=M32.10^^65^530^22
 ;;^UTILITY(U,$J,358.3,8318,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8318,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic
 ;;^UTILITY(U,$J,358.3,8318,1,4,0)
 ;;=4^M32.10
 ;;^UTILITY(U,$J,358.3,8318,2)
 ;;=^5011753
 ;;^UTILITY(U,$J,358.3,8319,0)
 ;;=M32.19^^65^530^24
 ;;^UTILITY(U,$J,358.3,8319,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8319,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic,Skin Involvmnt
 ;;^UTILITY(U,$J,358.3,8319,1,4,0)
 ;;=4^M32.19
 ;;^UTILITY(U,$J,358.3,8319,2)
 ;;=^5011759
 ;;^UTILITY(U,$J,358.3,8320,0)
 ;;=M32.9^^65^530^23
 ;;^UTILITY(U,$J,358.3,8320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8320,1,3,0)
 ;;=3^Lupus,Erythematosus,Systemic w/o Organ Involvmnt
 ;;^UTILITY(U,$J,358.3,8320,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,8320,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,8321,0)
 ;;=E88.1^^65^530^17
 ;;^UTILITY(U,$J,358.3,8321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8321,1,3,0)
 ;;=3^Lipodystrophy NOS
 ;;^UTILITY(U,$J,358.3,8321,1,4,0)
 ;;=4^E88.1
 ;;^UTILITY(U,$J,358.3,8321,2)
 ;;=^5003028
 ;;^UTILITY(U,$J,358.3,8322,0)
 ;;=C85.19^^65^530^2
 ;;^UTILITY(U,$J,358.3,8322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8322,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8322,1,4,0)
 ;;=4^C85.19
 ;;^UTILITY(U,$J,358.3,8322,2)
 ;;=^5001710
 ;;^UTILITY(U,$J,358.3,8323,0)
 ;;=C85.13^^65^530^5
 ;;^UTILITY(U,$J,358.3,8323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8323,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Intra-Abdominal Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8323,1,4,0)
 ;;=4^C85.13
 ;;^UTILITY(U,$J,358.3,8323,2)
 ;;=^5001704
 ;;^UTILITY(U,$J,358.3,8324,0)
 ;;=C85.16^^65^530^6
 ;;^UTILITY(U,$J,358.3,8324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8324,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Intrapelvic Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8324,1,4,0)
 ;;=4^C85.16
 ;;^UTILITY(U,$J,358.3,8324,2)
 ;;=^5001707
 ;;^UTILITY(U,$J,358.3,8325,0)
 ;;=C85.12^^65^530^7
 ;;^UTILITY(U,$J,358.3,8325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8325,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Intrathoracic Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8325,1,4,0)
 ;;=4^C85.12
 ;;^UTILITY(U,$J,358.3,8325,2)
 ;;=^5001703
 ;;^UTILITY(U,$J,358.3,8326,0)
 ;;=C85.14^^65^530^1
 ;;^UTILITY(U,$J,358.3,8326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8326,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Axilla/Upper Limb Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8326,1,4,0)
 ;;=4^C85.14
 ;;^UTILITY(U,$J,358.3,8326,2)
 ;;=^5001705
 ;;^UTILITY(U,$J,358.3,8327,0)
 ;;=C85.11^^65^530^3
 ;;^UTILITY(U,$J,358.3,8327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8327,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Head/Face/Neck Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8327,1,4,0)
 ;;=4^C85.11
 ;;^UTILITY(U,$J,358.3,8327,2)
 ;;=^5001702
 ;;^UTILITY(U,$J,358.3,8328,0)
 ;;=C85.15^^65^530^4
 ;;^UTILITY(U,$J,358.3,8328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8328,1,3,0)
 ;;=3^B-Cell Lymphoma,Unspec,Inguinal Region/LE Lymph Nodes
 ;;^UTILITY(U,$J,358.3,8328,1,4,0)
 ;;=4^C85.15
 ;;^UTILITY(U,$J,358.3,8328,2)
 ;;=^5001706
